

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC
Form 6-K
March 19, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending March 19, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notice of Annual General Meeting, 2007 Annual Report & 2007 Annual Review

GlaxoSmithKline plc issued its Notice of Annual General Meeting at 2.00pm (UK)
today, 19 March 2008.

The Company's Annual General Meeting will be held at 2.30pm on Wednesday 21 May
2008 at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster,

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

London SW1P 3EE.

Copies of the Company's Notice of Annual General Meeting, together with the 2007 Annual Report and 2007 Annual Review have been submitted to the UK Listing Authority, and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility which is situated at:

The Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
Tel: +44 (0) 20 7066 1000

These documents can also be viewed on the Company's website at www.gsk.com.

S M Bicknell
Company Secretary

19 March 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 19, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc